Active Ingredient(s): Bictegravir + Emtricitabine + Tenofovir Alafenamide
FDA Approved: * February 7, 2018
Category: HIV / AIDS

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Biktarvy Overview

Bictegravir (INN; formerly known as GS-9883)[1][2] is an investigational new drug of the integrase inhibitor class that was discovered by scientists at Gilead Sciences; in vitro and clinical results were presented by Gilead in the summer of 2016.[3] As of June 2016 Bictegravir was in a Phase 3 trial as part of a single tablet regimen in combination with tenofovir alafenamide (TAF) and emtricitabine (FTC) for the treatment of HIV-1 infection.[4] References ^ "Recommended INN: List 75" (PD...

Read more Biktarvy Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Biktarvy Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Bictegravir + Emtricitabine + Tenofovir Alafenamide
  • Tablet: 50mg + 200mg + 25mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Biktarvy: (1 result)

Sorted by National Drug Code
  • 61958-2501 Biktarvy Oral Tablet by Gilead Sciences, Inc.

Drugs with one or more similar ingredients: (16 results)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2018 and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 17 March 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.